Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

The European Commission’s approvals of TEVIMBRA in lung cancer are based on five randomized Phase 3 studies from the RATIONALE program. At ESMO 2025, BeOne will present new data from two of these ...

Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

Summit Therapeutics (Nasdaq: SMMT) said it plans to file a biologics license application in the fourth quarter for ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall ...

Summit Therapeutics Inc.’s presentation for bispecific antibody ivonescimab in non-small-cell lung cancer could draw some extra attention at next month’s World Conference on Lung Cancer meeting thanks ...

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced ...